|Bid||220.06 x 1100|
|Ask||220.51 x 800|
|Day's range||217.96 - 220.99|
|52-week range||187.16 - 351.86|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||21.55|
|Earnings date||20 Apr 2022 - 25 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||234.25|
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.